Cardiac Marker Testing Market Shares, Size & Growth 2024-2032
Cardiac Marker Testing Market Size & Share Global Analysis Report, 2024-2032

Cardiac Marker Testing Market Share, Size, Trends, Industry Analysis Report, By Product (Reagents and Kits and Instruments); By Biomarker Type; By End-User; By Region; Segment Forecast, 2024-2032

  • Published Date:Jan-2024
  • Pages: 116
  • Format: PDF
  • Report ID: PM3322
  • Base Year: 2023
  • Historical Data: 2019-2022

Report Outlook

The global cardiac marker testing market was valued at USD 4.7 billion in 2023 and is expected to grow at a CAGR of 8.60% during the forecast period. Increasing prevalence of acute coronary syndrome, high technological advancements in cardiac biomarkers, surge in the demand for point-of-care cardiac testing kits, and specificity for the detection of cardiac diseases are among the major factors fueling the growth of the global market. In addition, the growing popularity of these test kits mainly due to quick diagnosis and fast results obtained that reduces the diagnostic time involved and expediting the overall treatment process along with the rising focus on developing new and more advanced devices and test kits among key players are also likely to fuel the market growth. For instance, in February 2023, Avero Diagnostics, announced the launch of AMBLor, a lab test to identify early melanoma with very low risk of disease progression. The new test can identify the presence of the 2 biomarker proteins including AMBRA1 & Loricrin.

Cardiac Marker Testing Market Size

Moreover, robust research & development on the cardio-vascular interventions and focus on the novel biomarker tests among both government and private healthcare institutions through investing heavily in the R&D of biomarkers for the effective diagnosis, prognosis, & predictive analysis, that are creating significant opportunities for the market. Outbreak of the COVID-19 pandemic has significantly impacted the growth of the market. The emergence of deadly coronavirus also impacted the demand and adoption cardiac marker testing for a short-term, due to around fifty percent decrease in the number of patients with cardiovascular diseases and people who are diagnosed with myocardial infraction. However, there has been a rise in the demand for some tradition biomarkers and B-type natriuretic peptides, because of the increase in the incidences of heart failure during the pandemic.

The research study provides a comprehensive analysis of the industry, assessing the market on the basis of various segments and sub-segments. It sheds light on the competitive landscape and introduces Cardiac marker testing market key players from the perspective of market share, concentration ratio, etc. The study is a vital resource for understanding the growth drivers, opportunities, and challenges in the industry.

Industry Dynamics

Growth Drivers
Rising incidence of cardiovascular diseases across the globe has paved the way for greater adoption of advanced cardiac marker testing devices or systems, as these devices help in early detection and diagnosis of several CVD diseases including myocardial infraction, heart attack, heart failure, and acute coronary syndrome, that are anticipated to boost the demand and growth of the global cardiac marker testing market in the near future. For instance, as per statistics published by the WHO, cardiovascular diseases are leading cause of death across the globe with an accounting 17.9 million deaths, that represents about 32% of all global deaths.

Furthermore, the rapidly emerging markets like India and China are offering significant growth opportunities and potential for cardiac diagnostics because of the rising patient population and government focus on developing healthcare infrastructure with various new technologies and advancements in these countries.

Cardiac Marker Testing Market share

Report Segmentation

The market is primarily segmented based on product, biomarker type, end-user, and region.

By Product

By Biomarker Type

By Application

By Region

  • Reagents and Kits
  • Instruments
  • Troponin I and T
  • Creatine Kinase-MB (CK-MB)
  • Natriuretic Peptide
  • Myoglobin
  • High-Sensitivity C-Reactive Protein
  • Other Cardiac Biomarkers
  • Laboratory Testing Facilities
  • Point-Of-Care Testing Facilities
  • Academic Institutions
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

To Understand the Scope of this Report: Speak to Analyst

Reagents & kits segment accounted for the largest market share & is expected to maintain its dominance during forecast period

The reagents & kits segment accounted for major market share and is likely to retain its market position throughout the forecast period. The growth of the segment market can be highly attributable to rise in the number of cardiac biomarker tests performed all over the world mainly because of the high burden of various types of cardiovascular diseases and continuous growth in the global geriatric population. In addition, the increasing prevalence among major market players towards the introduction to new cardiac biomarker test kit to meet the rising need for fast diagnosis of CVD worldwide, are further likely to impact the growth of the segment market in a positive way.

The instruments segment is also expected to grow at considerable growth rate during the anticipated period, which is mainly driven by extensive rise in the need and prevalence for cardiac diagnostic and treatment devices and its rapidly increasing integration across several healthcare settings.

Troponin I and T segment held the largest market revenue share in 2022

The troponin I and T segment held the largest market revenue share with a healthy growth rate in 2022, on account of high preferences for these biomarkers for the diagnosis of acute myocardial infraction due to its comparative high-sensitivity and specificity. These types of high-sensitivity troponin assays help in detecting the protein quickly and at lower levels as compared to standard troponin tests. Additionally, it is also useful in the effective detection the risk of future heart events like heart attacks mainly in people with no symptoms, that are further contributing towards the market growth at rapid pace.

Natriuretic peptide segment is anticipated to grow at fastest growth rate over the course of study period, mainly due to its rapidly increasing usage for the detection of heart damage and stress and rising awareness among patients regarding the availability of these tests especially in developed countries like US, France, and Germany.

Point-of-care testing segment is expected to witness highest growth during forecast period

The point-of-care segment is expected to grow at a higher CAGR during the anticipated period, owing to growing use and adoption of several high-sensitive and easy-to-use POC troponin tests by healthcare service providers coupled with the increasing emphasis on providing effective and value-based services across the globe. Moreover, the rising need for these POC tests in nursing homes and also home healthcare due to exponential growth in the aging population, are some other factors projected to drive the segment market.

The laboratory testing segment led the industry market with considerable market share in 2022, which is highly accelerated by wide range of advantages and beneficial features offered by the laboratory testing like specificity, high-sensitivity, and cost-effectiveness along with the capabilities to facilitate the all kinds of testing and playing a crucial role in clinical decision-making.

Cardiac Marker Testing Market size

North America region dominated the global market in 2022

North America region dominated the global market with maximum revenue share, and is projected to maintain its dominance throughout the anticipated period. The regional market growth can be largely attributed to the presence of well-established and developed healthcare infrastructure and increasing adoption of cardiac biomarkers as a key tool for the diagnosis of several conditions. Moreover, the continuous rise in the geriatric population and high spending capacity of patients on their health, encourage them to get the best of available technology for the identification of conditions like acute myocardial infraction.

Asia Pacific registered robust growth rate over the study period, due to the growing affordability for innovated and advanced cardiac tests, modernization in healthcare infrastructure in APAC countries, and surge in the incidences of cardiovascular diseases. Moreover, the increasing government funding and favorable initiatives for target disease and other research and healthcare expenditure mainly in countries like India, China, and Malaysia, are further projected to fuel the demand and growth of the market in the region.

Cardiac Marker Testing Market share

Competitive Insight

Some of the major players operating in the global cardiac marker testing market include Roche, Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickson, Bio-Rad Laboratories, Thermo Fisher Scientific, LSI Medience, Quidel Corporation, Randox Laboratories, PerkinElmer, Tosoh Corporation, Alfa Scientific Designs, Response Biomedical, & Creative Diagnostics.

Recent Developments

  • In January 2022, PocDoc, a leading digital health platform and personal diagnostics provider, announced the launch of world-first smartphone-based cardiovascular test, that would be initially available to pharmacies, private healthcare providers, and NHS providers. Th new test will cover the complete five market lipid panel and company estimates that their technology will save the NHS million per year by reducing the number of required staffs.
  • In May 2022, Quidel Corporation developed a “Triage Cardiac Panel” to be used in the ED, which is FDA approved to aid in the diagnosis of the myocardial infraction. This is specially designed to deduce the level of creatine kine MB and myoglobin & troponin I.

Cardiac Marker Testing Market Report Scope

Report Attributes


Market size value in 2024

USD 5.01 billion

Revenue forecast in 2032

USD 9.73 billion


8.60% from 2024– 2032

Base year


Historical data

2019– 2022

Forecast period

2024– 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments covered

By Product, By Biomarker Type, By End-User, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickson and Company, Bio-Rad Laboratories Inc., Thermo Fisher Scientific, LSI Medience Corporation, Quidel Corporation, Randox Laboratories, PerkinElmer Inc., Tosoh Corporation, Alfa Scientific Designs, Response Biomedical, and Creative Diagnostics.

Explore the market dynamics of the 2024 Cardiac marker testing market share, size, and revenue growth rate, meticulously examined in the insightful reports crafted by Polaris Market Rersearch Industry Reports. 


The global cardiac marker testing market size is expected to reach USD 9.73 billion by 2032.

Key players in the cardiac marker testing market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickson, Bio-Rad Laboratories, Thermo Fisher Scientific.

North America contribute notably towards the global cardiac marker testing market.

The global cardiac marker testing market expected to grow at a CAGR of 8.43% during the forecast period.

The cardiac marker testing market report covering key segments are product, biomarker type, end-user, and region.